Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02633787 |
Recruitment Status :
Completed
First Posted : December 17, 2015
Results First Posted : November 6, 2016
Last Update Posted : November 6, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The aim of this study is to provide information on the persistence of bactericidal antibodies following Menactra booster vaccination in study MTA77 ( NCT01442675).
Objective:
- To evaluate the persistence of antibody responses (determined by a serum bactericidal assay using human complement (SBA-HC)) approximately 4 years after the administration of a booster dose of Menactra vaccine in trial MTA77
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Meningitis Meningococcal Meningitis Meningococcal Infections | Biological: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 110 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier |
Study Start Date : | December 2015 |
Actual Primary Completion Date : | February 2016 |
Actual Study Completion Date : | March 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Study Group
Participants received a booster dose of Menactra vaccine approximately four years earlier
|
Biological: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
No vaccine will be administered in this trial
Other Name: Menactra® |
- Percentage of Participants With Meningococcal Antibody Titers ≥ 1:4 Before, 28 Days After, and Approximately Four Years Following Menactra Vaccine Booster Vaccination. [ Time Frame: Pre-booster vaccination, 28 days, and 4 years post-booster vaccination ]Anti-meningococcal antibody titers for serogroups A, C, Y, and W-135 were measured using a serum bactericidal assay with human complement.
- Percentage of Participants With Meningococcal Antibody Titers ≥ 1:8 Before, 28 Days After, and Approximately Four Years Following Menactra Vaccine Booster Vaccination [ Time Frame: Pre-booster vaccination, 28 days and 4 years post-booster vaccination ]Anti-meningococcal antibody titers for serogroups A, C, Y, and W-135 were measured using a serum bactericidal assay with human complement.
- Geometric Mean Titers of Meningococcal Antibodies Before, 28 Days After, and Approximately Four Years Following Menactra Vaccine Booster Vaccination [ Time Frame: Pre-booster, 28 Days and 4 years post-booster vaccination ]Anti-meningococcal antibody titers for serogroups A, C, Y, and W-135 were measured using a serum bactericidal assay with human complement.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged ≥ 18 years on the day of inclusion
- Received booster dose of Menactra vaccine in trial MTA77
- Informed consent form has been signed and dated
- Able to attend the scheduled visit and to comply with all trial procedures.
Exclusion Criteria:
- Participation at the time of trial enrollment (or in the 4 weeks preceding trial enrollment) in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- Receipt of any meningococcal vaccine, including serogroup B meningococcal vaccine, after receipt of the booster dose of Menactra vaccine administered in trial MTA77
- Receipt of immune globulins, blood or blood-derived products in the past 3 months
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
- Bleeding disorder, thrombocytopenia, or receipt of anticoagulants contraindicating venipuncture at the discretion of the Investigator
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Current alcohol abuse or drug addiction
- Any illness that, in the opinion of the Investigator, might interfere with trial conduct or trial results
- Receipt of oral or injectable antibiotic therapy within 72 hours prior to the blood draw. (A prospective subject should not be included in the trial until 72 hours has passed.)
- Identified as an Investigator or employee of the Investigator or trial center with direct involvement in the proposed trial, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02633787
United States, Kentucky | |
Bardstown, Kentucky, United States, 40004 | |
United States, Massachusetts | |
Woburn, Massachusetts, United States, 01801 | |
United States, Michigan | |
Niles, Michigan, United States, 49120 | |
United States, Utah | |
Layton, Utah, United States, 84041 |
Study Director: | Medical Director | Sanofi Pasteur Inc. |
Responsible Party: | Sanofi Pasteur, a Sanofi Company |
ClinicalTrials.gov Identifier: | NCT02633787 |
Other Study ID Numbers: |
MTA00093 U1111-1161-3151 ( Other Identifier: WHO ) |
First Posted: | December 17, 2015 Key Record Dates |
Results First Posted: | November 6, 2016 |
Last Update Posted: | November 6, 2016 |
Last Verified: | September 2016 |
Meningitis Meningococcal Meningitis Meningococcal Infections Menactra® |
Meningococcal Infections Meningitis, Meningococcal Meningitis Infections Central Nervous System Diseases Nervous System Diseases Neisseriaceae Infections |
Gram-Negative Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Meningitis, Bacterial Central Nervous System Bacterial Infections Central Nervous System Infections |